Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | KDM6B | O15054 | 2/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.43 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623914 | 1.00 | ATR (0.47) | ATRADORA3ALDH1A1HPGDADORA1 | |
| SCHEMBL20745530 | 0.87 | ATR (0.48) | ATRADORA3ALDH1A1HPGDADORA1 | |
| SCHEMBL7844018 | 0.79 | FTO (0.58) | ALDH1A1HPGDKDM6BFTOEGLN1 | |
| SCHEMBL26776167 | 0.79 | FTO (0.40) | GSK3AGSK3BKDM6BFTOEGLN1 | |
| SCHEMBL25372618 | 0.77 | KDM4E (0.46) | ATRADORA3ALDH1A1HPGDADORA1 | |
| SCHEMBL20745449 | 0.76 | ALDH1A1 (0.47) | ATRADORA3ALDH1A1HPGDADORA1 | |
| SCHEMBL1920743 | 0.76 | PDCD1 (0.49) | ADORA3ALDH1A1HPGDADORA1ABL1 | |
| SCHEMBL2463088 | 0.75 | HSP90AA1 (0.53) | ATRADORA3ALDH1A1HPGDADORA1 | |
| SCHEMBL11906808 | 0.74 | ATR (0.53) | ATRADORA3ALDH1A1HPGDABL1 | |
| SCHEMBL24658797 | 0.72 | TP53 (0.52) | ALDH1A1HPGDVCPALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230183261-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| EP-3988555-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-111818916-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2020-10-23 | — | — | CN | disclosed |
| CN-111818917-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2020-10-23 | — | — | CN | disclosed |
| US-20200325153-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | ABBVIE INC (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3668502-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10676485-B2 | Macrocyclic MCL-1 inhibitors and methods of use | ABBVIE INC. (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3652184-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| US-20190144465-A1 | Macrocyclic MCL-1 inhibitors and methods of use | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-05-16 | — | — | US | disclosed |
| WO-2019035927-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035911-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676485-B2 | Macrocyclic MCL-1 inhibitors and methods of use | MCL1, BCL2A1, BCL2L10 | ATR 1150/4885ADORA3 531/4885ALDH1A1 641/4885 |
| US-20190144465-A1 | Macrocyclic MCL-1 inhibitors and methods of use | MCL1, BCL2A1, BCL2L10 | ATR 1157/4885ADORA3 616/4885ALDH1A1 724/4885 |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ATR 1150/4885ADORA3 531/4885ALDH1A1 641/4885 |
| US-20230183261-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | MCL1, BCL2A1, BCL2L10 | ATR 1150/4885ADORA3 531/4885ALDH1A1 641/4885 |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ATR 1150/4885ADORA3 531/4885ALDH1A1 641/4885 |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ATR 1150/4885ADORA3 531/4885ALDH1A1 641/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ATR 1150/4885ADORA3 531/4885ALDH1A1 641/4885 |
| US-20200325153-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | MCL1, BCL2A1, BCL2L10 | ATR 1150/4885ADORA3 531/4885ALDH1A1 641/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ATR 1150/4885ADORA3 531/4885ALDH1A1 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.